Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|10217||ETCTN||A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|AOST0331||COG||A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697): A Phase III Intergroup Study||Pediatric CIRB||Available to Open|
|NRG-BR002||NRG||A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA2186||ECOG-ACRIN||A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1208||ECOG||A Phase III Randomized; Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion||Adult CIRB - Late Phase Emphasis||Available to Open|
|10132||ETCTN||A Phase I Study of the Wee 1 kinase (Wee 1) inhibitor AZD1775 in combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)||Adult CIRB - Early Phase Emphasis||Available to Open|
|WF-10217||NCORP-Wake Forest University||Work Ability in Young Adult Survivors (WAYS)||Cancer Prevention and Control CIRB||Available to Open|
|S1800A||SWOG||A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|9950||ETCTN||A Phase I Study of M6620 (VX-970) in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)||Adult CIRB - Early Phase Emphasis||Available to Open|
|S1922||SWOG||Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|